Publication:
Multivalent ligand: Design principle for targeted therapeutic delivery approach

dc.contributor.authorChittasupho C.
dc.date.accessioned2021-04-05T03:33:57Z
dc.date.available2021-04-05T03:33:57Z
dc.date.issued2012
dc.date.issuedBE2555
dc.description.abstractMultivalent interactions of biological molecules play an important role in many biochemical events. A multivalent ligand comprises of multiple copies of ligands conjugated to scaffolds, allowing the simultaneous binding of multivalent ligands to multiple binding sites or receptors. Many research groups have successfully designed and synthesized multivalent ligands to increase the binding affinity, avidity and specificity of the ligand to the receptor. A multimeric ligand is a promising option for the specific treatment of diseases. In this review, the factors affecting multivalent interactions, including the size and shape of the ligand, geometry and an arrangement of ligands on the scaffold, linker length, thermodynamic, and kinetics of the interactions are discussed. Examples of the multivalent ligand applications for therapeutic delivery are also summarized. © 2012 Future Science Ltd.
dc.format.mimetypeapplication/pdf
dc.identifier.citationTherapeutic Delivery. Vol 3, No.10 (2012), p.1171-1187
dc.identifier.doi10.4155/tde.12.99
dc.identifier.issn20415990
dc.identifier.other2-s2.0-84867940749
dc.identifier.urihttps://hdl.handle.net/20.500.14740/6965
dc.rights.holderมหาวิทยาลัยศรีนครินทรวิโรฒ
dc.subject.otherAntibody
dc.subject.otherAntibody conjugate
dc.subject.otherArginylglycylaspartic acid
dc.subject.otherCancer vaccine
dc.subject.otherCarbohydrate
dc.subject.otherCephalosporin
dc.subject.otherCisplatin
dc.subject.otherCytotoxic T lymphocyte antigen 4 antibody
dc.subject.otherDendrimer
dc.subject.otherDoxorubicin
dc.subject.otherLigand
dc.subject.otherMacrogol
dc.subject.otherMultivalent ligand
dc.subject.otherNanoparticle
dc.subject.otherPeptide
dc.subject.otherPolyamidoamine
dc.subject.otherPolyglactin
dc.subject.otherPolymer
dc.subject.otherSingle chain fragment variable antibody
dc.subject.otherTumor antigen
dc.subject.otherTumor vaccine
dc.subject.otherUnclassified drug
dc.subject.otherVery late activation antigen 4
dc.subject.otherVitronectin receptor
dc.subject.otherAutoimmune disease
dc.subject.otherBinding affinity
dc.subject.otherBinding site
dc.subject.otherBreast cancer
dc.subject.otherCancer immunotherapy
dc.subject.otherConcentration (parameters)
dc.subject.otherConformational transition
dc.subject.otherControlled drug release
dc.subject.otherDensity
dc.subject.otherDrug delivery system
dc.subject.otherDrug half life
dc.subject.otherEncapsulation
dc.subject.otherEnthalpy
dc.subject.otherEntropy
dc.subject.otherHuman
dc.subject.otherIC 50
dc.subject.otherImmunogenicity
dc.subject.otherLigand binding
dc.subject.otherMolecular interaction
dc.subject.otherMolecularly targeted therapy
dc.subject.otherNonhuman
dc.subject.otherPriority journal
dc.subject.otherProtein multimerization
dc.subject.otherReview
dc.subject.otherT lymphocyte activation
dc.subject.otherThermodynamics
dc.subject.otherAnimals
dc.subject.otherBinding Sites
dc.subject.otherDrug Delivery Systems
dc.subject.otherDrug Design
dc.subject.otherHumans
dc.subject.otherLigands
dc.subject.otherThermodynamics
dc.titleMultivalent ligand: Design principle for targeted therapeutic delivery approach
dc.typeReview
dspace.entity.typePublication
swu.datasource.scopushttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84867940749&doi=10.4155%2ftde.12.99&partnerID=40&md5=7dacdc19cbff1ce1c4410b6d7493ae1c

Files